Could an arthritis drug boost leukemia treatment?
NCT ID NCT07392814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests adding tocilizumab, a drug used for arthritis, to standard chemotherapy (azacitidine and venetoclax) for adults with acute myeloid leukemia (AML) who cannot have intensive treatment. The main goal is to find a safe dose and check for side effects. Only 12 people will take part at one hospital in France.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tocilizumab
- What this could lead to
- If it works, this could point toward a more effective treatment for AML patients who cannot tolerate intensive chemotherapy.
- What could go wrong
- This is a very early phase 1 trial with only 12 participants, so safety and dosing are still being figured out. There is no guarantee the combination will work better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE MYELOID (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU of Nantes
Nantes, 44000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.